Policy & Regulation
Eli Lilly to purchase AurKa Pharma
16 May 2018 -

United States-based Eli Lilly and Company has agreed to acquire AurKa Pharma, a Canada-based cancer drug developer, from TVM Capital Life Science, it was reported yesterday.

The deal is valued at USD575m.

AurKa Pharma was established as part of the TVM Life Science Ventures VII fund, to develop an Aurora kinase A inhibitor called AK-01, an oncology compound that was originally discovered through a Lilly research and development program.

Under the terms of the transaction, Eli Lilly will pay an upfront payment of USD110m to AurKa Pharma shareholders. The Canadian firm will also be eligible to receive payments of up to USD465m in the form of regulatory and sales milestones, provided AK-01 is granted approved in the United States and other markets, and register certain sales levels.



Related Headlines